Apellis Pharmaceuticals Inc (APLS)
27.98
+0.72
(+2.64%)
USD |
NASDAQ |
Nov 01, 16:00
27.97
-0.01
(-0.04%)
After-Hours: 20:00
Apellis Pharmaceuticals Enterprise Value: 3.504B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 3.504B |
| October 31, 2024 | 3.416B |
| October 30, 2024 | 3.471B |
| October 29, 2024 | 3.435B |
| October 28, 2024 | 3.426B |
| October 25, 2024 | 3.346B |
| October 24, 2024 | 3.455B |
| October 23, 2024 | 3.382B |
| October 22, 2024 | 3.458B |
| October 21, 2024 | 3.370B |
| October 18, 2024 | 3.507B |
| October 17, 2024 | 3.497B |
| October 16, 2024 | 3.500B |
| October 15, 2024 | 3.500B |
| October 14, 2024 | 3.431B |
| October 11, 2024 | 3.402B |
| October 10, 2024 | 3.345B |
| October 09, 2024 | 3.373B |
| October 08, 2024 | 3.434B |
| October 07, 2024 | 3.440B |
| October 04, 2024 | 3.447B |
| October 03, 2024 | 3.514B |
| October 02, 2024 | 3.565B |
| October 01, 2024 | 3.475B |
| September 30, 2024 | 3.609B |
| Date | Value |
|---|---|
| September 27, 2024 | 3.686B |
| September 26, 2024 | 3.732B |
| September 25, 2024 | 3.822B |
| September 24, 2024 | 3.841B |
| September 23, 2024 | 4.081B |
| September 20, 2024 | 4.056B |
| September 19, 2024 | 4.570B |
| September 18, 2024 | 4.436B |
| September 17, 2024 | 4.423B |
| September 16, 2024 | 4.518B |
| September 13, 2024 | 4.678B |
| September 12, 2024 | 4.576B |
| September 11, 2024 | 4.768B |
| September 10, 2024 | 4.868B |
| September 09, 2024 | 4.960B |
| September 06, 2024 | 5.096B |
| September 05, 2024 | 4.881B |
| September 04, 2024 | 4.697B |
| September 03, 2024 | 4.822B |
| August 30, 2024 | 4.834B |
| August 29, 2024 | 4.812B |
| August 28, 2024 | 4.746B |
| August 27, 2024 | 4.919B |
| August 26, 2024 | 4.948B |
| August 23, 2024 | 4.981B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.140B
Minimum
Mar 17 2020
10.19B
Maximum
Jun 13 2023
4.400B
Average
4.224B
Median
Aug 05 2024
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 12.36B |
| Ionis Pharmaceuticals Inc | 5.311B |
| EyePoint Pharmaceuticals Inc | 365.18M |
| Cassava Sciences Inc | 1.050B |
| Macrogenics Inc | 102.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -37.66M |
| Revenue (Quarterly) | 199.68M |
| Total Expenses (Quarterly) | 229.13M |
| EPS Diluted (Quarterly) | -0.30 |
| Gross Profit Margin (Quarterly) | 88.43% |
| Profit Margin (Quarterly) | -18.86% |
| Earnings Yield | -9.79% |
| Normalized Earnings Yield | -9.748 |